Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Young

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
The Journal of Pediatrics|October 18, 2005
Health-related quality of life in overweight and nonoverweight black and white adolescentsErica M Fallon, Marian Tanofsky-Kraff, Anne-Caroline Norman, et al.
Obesity (Silver Spring, Md.)|March 26, 2018
Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures: Psychosocial DomainAngelina R Sutin, Kerri Boutelle, Susan M Czajkowski, et al.
Science Advances|April 20, 2019
Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogeneticsMikail Weston, Teresa Kaserer, Angela Wu, et al.
Population Health Management|February 18, 2011
Monitoring in diabetes self-management: issues and recommendations for improvementBarbara Stetson, David Schlundt, Mark Peyrot, et al.
Journal of Translational Medicine|June 1, 2010
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole bloodMaya Arai, Sadhana Jain, Amy A Weaver, et al.
Journal of Translational Medicine|May 28, 2010
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibodyYongjing Guo, Andrew A Hill, Renee C Ramsey, et al.
Pediatric Obesity|May 31, 2019
Weight-based teasing is associated with gain in BMI and fat mass among children and adolescents at-risk for obesity: A longitudinal studyNatasha A Schvey, Shannon E Marwitz, Sarah J Mi, et al.
Mabs|April 29, 2010
In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupusYulia Vugmeyster, Heath Guay, Pamela Szklut, et al.
Medical Care|May 11, 2021
Measuring Multimorbidity: Selecting the Right Instrument for the Purpose and the Data SourceJerry Suls, Elizabeth A Bayliss, Jay Berry, et al.
International Journal of Molecular Sciences|November 13, 2020
Platelet-Reactive Antibodies in Patients after Ischaemic Stroke-An Epiphenomenon or a Natural Protective MechanismYoung Eun Park, Rushi Penumarthy, Paul P Sun, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Pediatrics|October 18, 2005
Health-related quality of life in overweight and nonoverweight black and white adolescentsErica M Fallon, Marian Tanofsky-Kraff, Anne-Caroline Norman, et al.
Obesity (Silver Spring, Md.)|March 26, 2018
Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures: Psychosocial DomainAngelina R Sutin, Kerri Boutelle, Susan M Czajkowski, et al.
Science Advances|April 20, 2019
Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogeneticsMikail Weston, Teresa Kaserer, Angela Wu, et al.
Population Health Management|February 18, 2011
Monitoring in diabetes self-management: issues and recommendations for improvementBarbara Stetson, David Schlundt, Mark Peyrot, et al.
Journal of Translational Medicine|June 1, 2010
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole bloodMaya Arai, Sadhana Jain, Amy A Weaver, et al.
Journal of Translational Medicine|May 28, 2010
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibodyYongjing Guo, Andrew A Hill, Renee C Ramsey, et al.
Pediatric Obesity|May 31, 2019
Weight-based teasing is associated with gain in BMI and fat mass among children and adolescents at-risk for obesity: A longitudinal studyNatasha A Schvey, Shannon E Marwitz, Sarah J Mi, et al.
Mabs|April 29, 2010
In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupusYulia Vugmeyster, Heath Guay, Pamela Szklut, et al.
Medical Care|May 11, 2021
Measuring Multimorbidity: Selecting the Right Instrument for the Purpose and the Data SourceJerry Suls, Elizabeth A Bayliss, Jay Berry, et al.
International Journal of Molecular Sciences|November 13, 2020
Platelet-Reactive Antibodies in Patients after Ischaemic Stroke-An Epiphenomenon or a Natural Protective MechanismYoung Eun Park, Rushi Penumarthy, Paul P Sun, et al.
Pageof 11